Therapeutic Asset Ratings

480 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
VEMURAFENIB Solid Tumor	Seoul National University Bundang Hospital	P2	CCC (54)
Abemaciclib Solid Tumor	Tango Therapeutics, Inc.	P2	CCC (53)
Busulphan Solid Tumor	University of Rochester	P2	CCC (53)
Selinexor Solid Tumor	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Alpelisib Solid Tumor	Tianjin Medical University Second Hospital	P2	CCC (52)
Pemigatinib Solid Tumor	UNICANCER	P2	CCC (52)
Rapamycin Solid Tumor	Albert Einstein College of Medicine	P2	CCC (52)
gsk2110183 Solid Tumor	Laekna Limited	P1/2	CCC (52)
Hycamtin Solid Tumor	National Cancer Institute (NCI)	P1/2	CCC (52)
Indocyanine Green Solid Tumor	University of Pennsylvania	P1/2	CCC (52)
Hydroxychloroquine Solid Tumor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P2	CCC (51)
Senaparib Solid Tumor	Impact Therapeutics, Inc.	P1	CCC (51)
Absk061 Solid Tumor	Abbisko Therapeutics Co, Ltd	P2	CCC (50)
Acetylsalicylic Acid Solid Tumor	Val Adams	P2	CCC (50)
Autologous Cd1C+ /Cd141+ Mydc Solid Tumor	Universitair Ziekenhuis Brussel	P2	CCC (50)
Avutometinib Solid Tumor	Memorial Sloan Kettering Cancer Center	P2	CCC (50)
Defactinib Solid Tumor	University of Oklahoma	P2	CCC (50)
Ensartinib Solid Tumor	Nanjing First Hospital, Nanjing Medical University	P2	CCC (50)
Envafolimab Solid Tumor	3D Medicines (Sichuan) Co., Ltd.	P2	CCC (50)
Givastomig Solid Tumor	I-Mab Biopharma US Limited	P2	CCC (50)
Hrs-4508 Solid Tumor	Jiangsu HengRui Medicine Co., Ltd.	P2	CCC (50)
Inavolisib Solid Tumor	Hoffmann-La Roche	P2	CCC (50)
Jab-21822 Solid Tumor	Allist Pharmaceuticals, Inc.	P2	CCC (50)
Lipitor Solid Tumor	Joaquina Baranda	P2	CCC (50)
Regorafenib Solid Tumor	Helsinki University Central Hospital	P2	CCC (50)

Showing 51 to 75 of 480 assets

PreviousPage 3 of 20Next